CN1098249C - 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途 - Google Patents
乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途 Download PDFInfo
- Publication number
- CN1098249C CN1098249C CN95107019A CN95107019A CN1098249C CN 1098249 C CN1098249 C CN 1098249C CN 95107019 A CN95107019 A CN 95107019A CN 95107019 A CN95107019 A CN 95107019A CN 1098249 C CN1098249 C CN 1098249C
- Authority
- CN
- China
- Prior art keywords
- ubimec
- medication
- treatment
- hepatitis
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010019799 Hepatitis viral Diseases 0.000 title claims abstract description 25
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 81
- 201000001862 viral hepatitis Diseases 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 61
- 108020004414 DNA Proteins 0.000 description 36
- 210000002966 serum Anatomy 0.000 description 26
- 241000725618 Duck hepatitis B virus Species 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- 241000700605 Viruses Species 0.000 description 14
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 12
- 208000006454 hepatitis Diseases 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 241000272525 Anas platyrhynchos Species 0.000 description 10
- 206010008909 Chronic Hepatitis Diseases 0.000 description 7
- 101710142246 External core antigen Proteins 0.000 description 7
- 229960004150 aciclovir Drugs 0.000 description 7
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 102000003929 Transaminases Human genes 0.000 description 5
- 108090000340 Transaminases Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 3
- 208000037262 Hepatitis delta Diseases 0.000 description 3
- 241000724709 Hepatitis delta virus Species 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZKHSPLCIOVILMA-UHFFFAOYSA-N 2-(2-phenylphenyl)ethanol Chemical compound OCCC1=CC=CC=C1C1=CC=CC=C1 ZKHSPLCIOVILMA-UHFFFAOYSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102100032126 Aminopeptidase B Human genes 0.000 description 1
- 241000272522 Anas Species 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- APMKTRFFUIKGGQ-UHFFFAOYSA-N C(=O)O.[P] Chemical compound C(=O)O.[P] APMKTRFFUIKGGQ-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- -1 Zidovodine Chemical compound 0.000 description 1
- UDMBCSSLTHHNCD-UHTZMRCNSA-N [(2r,3s,4s,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O UDMBCSSLTHHNCD-UHTZMRCNSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 108090000449 aminopeptidase B Proteins 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (2)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN95107019A CN1098249C (zh) | 1995-06-21 | 1995-06-21 | 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途 |
US08/973,958 US6245813B1 (en) | 1995-06-21 | 1996-06-21 | Use of ubenimex and the pharmaceutical composition containing it for treating virus hepatitis |
PCT/CN1996/000046 WO1997000677A1 (fr) | 1995-06-21 | 1996-06-21 | Utilisation de l'ubenimex et de la composition pharmaceutique le renfermant pour le traitement de l'hepatite virale |
JP9503498A JPH11508247A (ja) | 1995-06-21 | 1996-06-21 | ウベニメクス及びウベニメクスを含む医薬組成物のウイルス性肝炎の治療薬としての用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN95107019A CN1098249C (zh) | 1995-06-21 | 1995-06-21 | 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1138572A CN1138572A (zh) | 1996-12-25 |
CN1098249C true CN1098249C (zh) | 2003-01-08 |
Family
ID=5076182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95107019A Expired - Fee Related CN1098249C (zh) | 1995-06-21 | 1995-06-21 | 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US6245813B1 (zh) |
JP (1) | JPH11508247A (zh) |
CN (1) | CN1098249C (zh) |
WO (1) | WO1997000677A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040228168A1 (en) * | 2003-05-13 | 2004-11-18 | Richard Ferrant | Semiconductor memory device and method of operating same |
JP6672528B2 (ja) * | 2016-09-05 | 2020-03-25 | 呈和科技股▲ふん▼有限公司Gch Technology Co.,Ltd. | ソルビトールトリアセタールおよびモノアセタールを含む透明核剤組成物 |
CN106317451B (zh) | 2016-09-05 | 2019-02-12 | 呈和科技股份有限公司 | 一种包含微量芳醛、山梨醇二缩醛和山梨醇三缩醛的成核剂组合物 |
US10588880B2 (en) | 2016-09-28 | 2020-03-17 | Eiger Biopharmaceuticals, Inc. | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis |
CA3082178A1 (en) * | 2017-11-28 | 2019-06-06 | Eiger Biopharmaceuticals, Inc. | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4308256A (en) * | 1980-09-19 | 1981-12-29 | American Home Products Corporation | Method of inducing analgesia |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5439477B2 (zh) * | 1974-07-01 | 1979-11-28 | ||
JPS609487A (ja) * | 1983-06-29 | 1985-01-18 | Kunio Yamane | 組換dna分子 |
JPS6272613A (ja) * | 1985-09-25 | 1987-04-03 | Microbial Chem Res Found | 播種性血管内凝固症候群予防・治療剤 |
JPH04193827A (ja) * | 1990-11-26 | 1992-07-13 | Nippon Kayaku Co Ltd | 慢性骨髄性白血病治療剤 |
-
1995
- 1995-06-21 CN CN95107019A patent/CN1098249C/zh not_active Expired - Fee Related
-
1996
- 1996-06-21 US US08/973,958 patent/US6245813B1/en not_active Expired - Fee Related
- 1996-06-21 JP JP9503498A patent/JPH11508247A/ja active Pending
- 1996-06-21 WO PCT/CN1996/000046 patent/WO1997000677A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4308256A (en) * | 1980-09-19 | 1981-12-29 | American Home Products Corporation | Method of inducing analgesia |
Also Published As
Publication number | Publication date |
---|---|
WO1997000677A1 (fr) | 1997-01-09 |
US6245813B1 (en) | 2001-06-12 |
CN1138572A (zh) | 1996-12-25 |
JPH11508247A (ja) | 1999-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101466392B (zh) | 用于预防或治疗hiv感染的药用组合物及其应用 | |
CN88101606A (zh) | 利用双链核糖核酸与病毒抑制剂联合以治疗人病毒感染 | |
CN1050995C (zh) | 通过系统的dsRNA治疗使宿主防御介质进入生物液体中 | |
CN1882335A (zh) | Hcv感染的组合疗法 | |
CN1059659A (zh) | 病毒性肝炎的诊断和治疗 | |
CN103458913A (zh) | 对乙型肝炎病毒感染或其与丁型肝炎病毒感染及相关肝脏疾病结合的治疗 | |
CN1098249C (zh) | 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途 | |
CN1899279A (zh) | 绿原酸在制备具有保护肝脏功效药物的用途 | |
CN1087829A (zh) | 治疗乙肝的组合物及其方法 | |
CN1072961C (zh) | 治疗对干扰素治疗无反应者的丙型肝炎的方法 | |
CN1857259A (zh) | 用于预防和/或治疗肝脏疾病的药物组合物 | |
CN100443117C (zh) | 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途 | |
CN100342909C (zh) | 一种胸腺素α1的水溶液制剂、其制备方法及应用 | |
CN1225249C (zh) | 一种提高免疫力的抗病毒药及制备方法 | |
KR100394382B1 (ko) | 천연사람α-인터페론으로구성된약학조성물 | |
CN1911958A (zh) | 一种抑制p38激酶活性的多肽及其应用 | |
CN1182848C (zh) | 布拉他辛在制备抑制艾滋病病毒的药物中的应用 | |
Park et al. | Adjuvant effect of polyadenylic. polyuridylic acid on antibody production of recombinant hepatitis B surface antigen in mice | |
Levy | Polynucleotides as interferon inducers and immune modulators | |
Sevastos et al. | Acute Pancreatitis Associated WithSalmonella Enteritidis | |
CN1305527C (zh) | 乙型肝炎治疗疫苗及其制备方法 | |
Gust | Two antigenic specificities in the Australia antigen | |
El-Reshaid et al. | Rituximab Treatment for Recurrent Skin Vasculitis Due to Cryoglobulinemia Associated with Hepatitis C Despite Viral Clearance with Sofosbuvir | |
CN1275646C (zh) | 重组人干扰素α2b滴鼻剂及其制备方法 | |
CN1045723C (zh) | 土贝母苷甲注射液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SICHUAN INDUSTRIAL INSTITUTE OF ANTIBIOTICS CO., Free format text: FORMER OWNER: SICHUAN ANTIMICROBIAL INDUSTRY RESEARCH INSTITUTE, STATE MEDICINES ADMINISTRATION Effective date: 20070824 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070824 Address after: 610051, No. 9, Banqiao Road, Chengdu, Sichuan Patentee after: Sichuan Industrial institute of antibiotics Co., Ltd. Address before: 610051, No. 9, Banqiao Road, Chengdu, Sichuan Patentee before: Sichuan Inst. of Antibiotic Industry, State Pharmaceutical Administration |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030108 |